Following the terminated partnership with Sanofi, MannKind has relaunched its ultra-rapid-acting inhaled (needle free) mealtime insulin, Afrezza. Afrezza is an ultra-rapid-acting insulin for people with type 1 and 2 diabetes, peaking in only 16-21 minutes versus about 60-90 minutes for current injected rapid-acting insulins such as Humalog and Novolog .